Standard
Abbott Receives FDA De Novo Authorization for Libre Duo 10 Day Continuous Glucose and Ketone Monitoring System
The U.S. Food and Drug Administration (FDA) has granted de novo authorization to Abbott for the Libre Duo 10 Day, the world’s first integrated dual-analyte sensor designed to continuously monitor both glucose and ketone levels. This regulatory milestone marks a significant shift in the management of diabetes, moving beyond traditional glucose-only tracking to provide a…
